Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
Dividends
Alto Neuroscience, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.02%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Alto Neuroscience, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Alpha Tau Medical Ltd NASDAQ:DRTS | $1.24B | 0.00% | $0.00 | 0.00% | 0.00% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | 0.00% | $0.00 | 0.00% | 0.00% |
Contineum Therapeutics, Inc. NASDAQ:CTNM | $348.58M | 0.00% | $0.00 | 0.00% | 0.00% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | 0.00% | $0.00 | 0.00% | 0.00% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | 0.00% | $0.00 | 0.00% | 0.09% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | 0.00% | $0.00 | 0.00% | 0.00% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | 0.00% | $0.00 | 0.00% | 0.00% |
Korro Bio, Inc. NASDAQ:KRRO | $196.29M | 0.00% | $0.00 | 0.00% | 0.00% |
Cellectis S.A. NASDAQ:CLLS | $118.86M | 0.00% | $0.00 | 0.00% | 0.00% |
Aldeyra The NASDAQ:ALDX | $38.86M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about ANRO's dividend, answered from reported figures.
Does ANRO stock pay dividends?
Alto Neuroscience, Inc. (ANRO) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is ANRO's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.